FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)

View source ↗

Summary

FDA approved a supplemental Biologics License Application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc., updating its labeling/permitted indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• OGIVRI (trastuzumab-dkst)

Snippet

SUPPL AP for OGIVRI (TRASTUZUMAB-DKST)